The FDA issued a complete response letter for Regeneron’s lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts seen progress in Biogen’s turnaround.
Elevate your perspective with NextTech Info, the place innovation meets notion.
Uncover the latest breakthroughs, get distinctive updates, and be a part of with a world neighborhood of future-focused thinkers.
Unlock tomorrow’s traits as we converse: be taught additional, subscribe to our publication, and develop to be part of the NextTech neighborhood at NextTech-news.com
Keep forward of the curve with NextBusiness 24. Discover extra tales, subscribe to our publication, and be a part of our rising neighborhood at nextbusiness24.com